The Post–R-CHOP Era: Novel Therapies and Evolving Standards in Aggressive Lymphoma

The treatment landscape for aggressive B-cell lymphomas is rapidly evolving beyond the longstanding R-CHOP paradigm. Recent data f have established polatuzumab vedotin plus R-CHP as a frontline standard for selected high-risk patients, while novel immunotherapy-based combinations such as tafasitamab/lenalidomide plus R-CHOP and epcoritamab plus R-CHOP are demonstrating encouraging efficacy in earlier treatment settings. In relapsed or refractory disease, CAR T-cell therapy continues to redefine second-line management, and CD20×CD3 bispecific antibodies are expanding effective off-the-shelf treatment options. This session , led by Dr. Sarah Rutherford, will review the latest evidence, emerging standards of care, and practical strategies for integrating these advances into contemporary clinical practice.